Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.235 -0.035 (-2.76%)
Delayed Quote Updated: 1:23 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 384,443
Open 1.270
Bid (Size) 1.230 (5,500)
Ask (Size) 1.240 (7,600)
Prev. Close 1.270
Today's Range 1.220 - 1.285
52wk Range 1.220 - 3.535
Shares Outstanding 60,705,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-22.3%
-22.3%
1 Month
-19.8%
-19.8%
3 Month
-29.8%
-29.8%
6 Month
-37.9%
-37.9%
1 Year
-47.0%
-47.0%

More News

Read More
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
News headline image
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗
Via MarketBeat
News headline image
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?
Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
What is the current price of Caribou Biosciences, Inc. - Common Stock?
The current price of Caribou Biosciences, Inc. - Common Stock is 1.235
When was Caribou Biosciences, Inc. - Common Stock last traded?
The last trade of Caribou Biosciences, Inc. - Common Stock was at 10/01/26 01:23 PM ET
What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
The market capitalization of Caribou Biosciences, Inc. - Common Stock is 74.97M
How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
Caribou Biosciences, Inc. - Common Stock has 75M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.